PD 0360324

Phase 3Small molecule

Pfizer

PD 0360324 is one of 205 small molecule programs targeting Pulmonary Sarcoidosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

204

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pulmonary SarcoidosisActive, not recruiting

InsomniaActive, not recruiting

Interstitial CystitisActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

Generalized Anxiety DisorderActive, not recruiting

Cutaneous Lupus ErythematosusActive, not recruiting

Pulmonary SarcoidosisPhase 2

Active, not recruiting

InsomniaPhase 2

Active, not recruiting

Interstitial CystitisPhase 2

Active, not recruiting

Rheumatoid ArthritisPhase 1

Active, not recruiting

Generalized Anxiety DisorderPhase 3

Active, not recruiting

Cutaneous Lupus ErythematosusPhase 1

Active, not recruiting

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

PD 0360324

Pfizer

Phase 3

1 2

Orencia

Bristol-Myers Squibb

Preclinical

47 3

Cimzia

UCB

Preclinical

30 4

Remicade

OOrganon and Co

Preclinical

43 5

Enbrel

IImmunex

Preclinical

64 6

Arcoxia

Novartis

Preclinical

4 7

Kevzara

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

14 8

Kineret

SSwedish Orphan Biovitrum

Preclinical

6 9

Rituxan

Pfizer

Preclinical

7 10

Velcade

SShilpa Grover, MD, MPH

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Generalized Anxiety Disorder7 trials

A 5-Week Trial Of PD 0332334 And Alprazolam Extended Release Compared To Placebo In Patients With Generalized Anxiety Disorder

Completed· Pfizer logo

Pfizer·Phase 2·NCT00921063·222 enrolled

A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)

Terminated· Pfizer logo

Pfizer·Phase 3·NCT00735267·468 enrolled

A 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder

Completed· Pfizer logo

Pfizer·Phase 3·NCT00542685·551 enrolled

Show 4 more trials

A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)

Terminated· Pfizer logo

Pfizer·Phase 3·NCT00658372·360 enrolled

A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1)

Terminated· Pfizer logo

Pfizer·Phase 3·NCT00658008·501 enrolled

A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder (3)

Terminated· Pfizer logo

Pfizer·Phase 3·NCT00658762·286 enrolled

6-Month Open-Label Safety Study Of PD 0332334 In Elderly Patients With Generalized Anxiety Disorder (GAD)

Withdrawn· Pfizer logo

Pfizer·Phase 3·NCT00738738

Insomnia3 trials

A Dose-ranging, Multicenter Polysomnography Trial of PD 0200390 in Adults With Primary Insomnia

Completed· Pfizer logo

Pfizer·Phase 2·NCT00551148·92 enrolled

A Dose-Ranging, Multicenter Polysomnography Trial of PD 0200390 in Elderly Subjects With Primary Insomnia

Withdrawn· Pfizer logo

Pfizer·Phase 2·NCT00748592

A Randomized, Double Blind, Parallel Group, Placebo Controlled, Multicenter Outpatient Trial Of PD 0200390 In Adults With Primary Insomnia

Completed· Pfizer logo

Pfizer·Phase 2·NCT00569972·682 enrolled

Absorption2 trials

An Open-label Study to Investigate the Absorption, Metabolism and Excretion of Radiolabeled PD 0332334 in Six Healthy Male Volunteers

Completed· Pfizer logo

Pfizer·Phase 1·NCT00537615·6 enrolled

A Study To Investigate The Absorption, Metabolism And Excretion Of [14C] PD 0200390 In Six Healthy Male Volunteers

Completed· Pfizer logo

Pfizer·Phase 1·NCT00722306·6 enrolled

Knee Surgery1 trial

Evaluation of PD 0348292 for Preventing Blood Clots in the Lungs or Deep Leg Veins of Patients After Knee Surgery

Completed· Pfizer logo

Pfizer·Phase 2·NCT00306254·1,225 enrolled

Metformin1 trial

Investigation Of How PD 0332334 And Metformin Are Eliminated From The Body When They Are Administered At The Same Time

Terminated· Pfizer logo

Pfizer·Phase 1·NCT00809536·24 enrolled

10 more indications

Double-blind1 trial

A Double-blind, Parallel Group, Placebo-Controlled Outpatient Trial of PD 00200390 in Adults With Nonrestorative Sleep

Completed· Pfizer logo

Pfizer·Phase 2·NCT00655369·306 enrolled

Regular Hemodialysis1 trial

A Single Dose Study Investigating The Elimination Of PD-0332334 In Patients Receiving Regular Hemodialysis

Completed· Pfizer logo

Pfizer·Phase 1·NCT00730145·8 enrolled

Phase 11 trial

A Phase 1 Study To Estimate The Effects Of PD 0332334 On Lithium Pharmacokinetics In Healthy Subjects

Withdrawn· Pfizer logo

Pfizer·Phase 1·NCT00820794

Interstitial Cystitis1 trial

An Effectiveness And Safety Study Of PD 0299685 For The Treatment Of Symptoms Associated With Interstitial Cystitis

Completed· Pfizer logo

Pfizer·Phase 2·NCT00739739·161 enrolled

Single Dose1 trial

A Single Dose Study Investigating the Elimination as Well as the Tolerability of PD 0332334 in Healthy Subjects as Compared to Patients With Impaired Kidney Function.

Terminated· Pfizer logo

Pfizer·Phase 1·NCT00721422·16 enrolled

Cutaneous Lupus Erythematosus1 trial

A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus

Terminated· Pfizer logo

Pfizer·Phase 1·NCT01470313·28 enrolled

Rheumatoid Arthritis1 trial

Dose-Escalating Multiple Dose Study of PD-0360324 in Combination With Methotrexate in Patients With Rheumatoid Arthritis

Completed· Pfizer logo

Pfizer·Phase 1·NCT00550355·78 enrolled

Pulmonary Sarcoidosis1 trial

A Phase 2, Safety, Tolerability, and Efficacy Study of PD 0360324 in Chronic Pulmonary Sarcoidosis

Terminated· Pfizer logo

Pfizer·Phase 2·NCT01732211·1 enrolled

Advanced Malignancies1 trial

A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)

Terminated· Pfizer logo

Pfizer·Phase 1/2·NCT02554812·409 enrolled

Unspecified1 trial

Evaluating The Effects Of Cimetidine On The Elimination Of PD 0332334 From The Body

Terminated· Pfizer logo

Pfizer·Phase 1·NCT00800280·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 24 trial records for PD 0360324. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PD 0360324 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PD 0360324. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Pfizer

PD 0360324

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Generalized Anxiety Disorder7 trials

Insomnia3 trials

Absorption2 trials

Knee Surgery1 trial

Metformin1 trial

Double-blind1 trial

Regular Hemodialysis1 trial

Phase 11 trial

Interstitial Cystitis1 trial

Single Dose1 trial

Cutaneous Lupus Erythematosus1 trial

Rheumatoid Arthritis1 trial

Pulmonary Sarcoidosis1 trial

Advanced Malignancies1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News